$CTSO Income Statement | Understand Stock

$CTSO

$5.24 +$0.39 (8.04%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue, net
Product sales
CytoSorb sales
Other product sales
Total product sales
Grant income
Total revenue, net
Cost of goods sold
Gross profit
Operating expenses:
Research and development
Legal, financial and other consulting
Research and development, net of grant income
Selling, general and administrative
Restructuring
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Gain (loss) on foreign currency transactions
Miscellaneous expense
Miscellaneous income (expense)
Loss on abandoned patents
Total other income (expense), net

Loss before benefit from income taxes
Benefit from income taxes
Net loss
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax
Comprehensive loss
Basic net loss per common share (in dollars per share)
Diluted net loss per common share (in dollars per share)
Weighted average number of shares of common stock outstanding, basic (in shares)
Weighted average number of shares of common stock outstanding, diluted (in shares)

Comments